Scarica l'app Stockscreener
166.28
0.78%
1.29
Dopo l'orario di chiusura:
166.27
-0.010
-0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$164.99
Aprire:
$165.62
Volume 24 ore:
6.73M
Relative Volume:
1.37
Capitalizzazione di mercato:
$293.80B
Reddito:
$55.53B
Utile/perdita netta:
$5.12B
Rapporto P/E:
45.56
EPS:
3.65
Flusso di cassa netto:
$15.62B
1 W Prestazione:
-4.67%
1M Prestazione:
-11.96%
6M Prestazione:
-0.08%
1 anno Prestazione:
+20.23%
Intervallo 1D:
$164.80
$166.74
Intervallo di 1 settimana:
$164.72
$176.63
Portata 52W:
$137.14
$207.32
Abbvie Inc Stock (ABBV) Company Profile
Nome
Abbvie Inc
Settore
Industria
Telefono
(847) 932-7900
Indirizzo
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Confronta ABBV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ABBV | 166.28 | 293.80B | 55.53B | 5.12B | 15.62B | 3.65 |
| LLY | 727.20 | 683.37B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 99.81 | 446.14B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.77 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| MRK | 96.56 | 242.49B | 63.17B | 12.15B | 14.84B | 1.80 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-12-11 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-07-25 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-04-05 | Downgrade | Argus | Buy → Hold |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2023-02-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-11-08 | Downgrade | Societe Generale | Buy → Hold |
| 2022-08-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Underperform |
| 2022-05-06 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-02-28 | Downgrade | UBS | Buy → Neutral |
| 2022-02-03 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-03 | Reiterato | Barclays | Equal Weight |
| 2022-02-03 | Reiterato | BofA Securities | Neutral |
| 2022-02-03 | Reiterato | Goldman | Neutral |
| 2022-01-13 | Iniziato | Redburn | Buy |
| 2022-01-12 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-11-23 | Aggiornamento | Societe Generale | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-23 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Aggiornamento | Argus | Hold → Buy |
| 2020-05-18 | Ripresa | BofA/Merrill | Neutral |
| 2020-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Ripresa | Morgan Stanley | Overweight |
| 2020-04-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Reiterato | Cowen | Outperform |
| 2019-09-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-20 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-04-29 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
Mostra tutto
Abbvie Inc Borsa (ABBV) Ultime notizie
AbbVie Inc. (NYSE:ABBV) Short Interest Up 12.1% in October - MarketBeat
AbbVie snaps eight straight sessions of losses - Seeking Alpha
AbbVie (NYSE:ABBV) Trading Up 0.2%Time to Buy? - MarketBeat
Mawer Investment Management Ltd. Sells 14,746 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe - Yahoo Finance
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products - AbbVie
Allergan Aesthetics Launches Free Business Training Platform for Healthcare Practices | ABBV Stock News - StockTitan
GLOBALT Investments LLC GA Invests $3.78 Million in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Bought by Richard C. Young & CO. LTD. - MarketBeat
Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal | ALDX Stock News - StockTitan
Aljian Capital Management LLC Invests $1.33 Million in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by MAI Capital Management - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by AMG National Trust Bank - MarketBeat
AbbVie bags EU nod for key drug from ImmunoGen takeover - pharmaphorum
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer - MarketWatch
AbbVie’s Elahere wins European approval for certain ovarian cancers - Pharmaceutical Technology
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer - PR Newswire
AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year - Yahoo Finance
Atlanta Consulting Group Advisors LLC Acquires Shares of 5,060 AbbVie Inc. (NYSE:ABBV) - MarketBeat
Sawgrass Asset Management LLC Has $13.61 Million Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Mutual of America Capital Management LLC Has $46.17 Million Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Why AbbVie’s (ABBV) Drug Setback Creates A Prime Buy-The-Dip Moment - MSN
Natixis Advisors LLC Has $239.62 Million Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Mizuho Securities USA LLC Reduces Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Mizuho Markets Americas LLC Decreases Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Dividend King AbbVie Just Paid Investors: Here's How Much They Got - 24/7 Wall St.
Kentucky Retirement Systems Insurance Trust Fund Has $10.33 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Kentucky Retirement Systems Sells 10,016 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Ipswich Investment Management Co. Inc. Sells 19,650 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Coastline Trust Co - MarketBeat
Wolfe Research Initiates Coverage of AbbVie (ABBV) with Outperform Recommendation - Nasdaq
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
AbbVie (NYSE:ABBV) Shares Down 1.7%Should You Sell? - MarketBeat
AbbVie Stock Falls 11% In A Month: Should You Buy The Dip? - Barchart
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip? - MSN
Simplify Asset Management Inc. Takes Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Empowered Funds LLC - MarketBeat
AbbVie, Bitcoin And An Energy Stock On CNBC's 'Final Trades' - Benzinga
Dearborn Partners LLC Has $42.34 Million Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
CIBC Asset Management Inc Grows Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Intellectus Partners LLC Decreases Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
OneDigital Investment Advisors LLC Decreases Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock - MSN
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
AbbVie Target of Unusually Large Options Trading (NYSE:ABBV) - MarketBeat
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
AbbVie shares trade in the red for seventh straight session (NYSE:ABBV) - Seeking Alpha
ABBV: 3 Dividend Powerhouses Yielding Over 3% to Consider - StockNews.com
AbbVie Inc. (NYSE:ABBV) Shares Sold by ING Groep NV - MarketBeat
AbbVie (NYSE:ABBV) Trading Down 0.5% on Analyst Downgrade - MarketBeat
Tokio Marine Asset Management Co. Ltd. Purchases 3,304 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Abbvie Inc Azioni (ABBV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.26%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):